Investors & Media Press Releases

Press Releases

Summary Toggle

09.15.2020

Summary Toggle Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership

Summary TogglePartnership secures access to cGMP capacity and resources at Viralgen to support the development and commercialization of Axovant’s AAV gene therapy programs for GM1 and GM2 gangliosidosis Partnership bolsters the Company’s clinical and commercial capacity and expands access to process development,
Read More

PDF Version
Read More
Summary Toggle

09.08.2020

Summary Toggle Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences"

Summary Toggle - Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran , MD, Chief R&D Officer, on October 30 th , 2020, with leading movement disorder specialists NEW YORK and BASEL, Switzerland , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (Nasdaq: AXGT), a clinical-stage company
Read More

PDF Version
Read More
Summary Toggle

08.11.2020

Summary Toggle Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2020

Summary ToggleData readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020 Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PD Company had $55.5 million of cash and cash equivalents as of June 30, 2020 NEW YORK and BASEL, Switzerland , Aug.
Read More

PDF Version
Read More
Summary Toggle

07.31.2020

Summary Toggle Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD

Summary ToggleNEW YORK and BASEL, Switzerland , July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, announced today that its subsidiary has signed a three-year Clinical Supply Agreement (“CSA”) with
Read More

PDF Version
Read More
Summary Toggle

06.10.2020

Summary Toggle Axovant Announces Year-End Financial Results and Expected Key Clinical Milestones in Q4 2020

Summary ToggleCompleted enrollment of cohort 2 of SUNRISE-PD Phase 2 study of AXO-Lenti-PD in Parkinson’s disease, with data from this cohort expected in Q4 2020 Completed enrollment of low-dose cohort of Phase 1/2 clinical study of AXO-AAV-GM1 for GM1 gangliosidosis, with data from this cohort expected in Q4
Read More

PDF Version
Read More
Summary Toggle

06.08.2020

Summary Toggle Axovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I (Infantile Onset) Patients with GM1 Gangliosidosis

Summary Toggle- Six-month data from low-dose cohort expected in Q4 2020 - IND amended to include Type I (infantile onset) patients and to evaluate a higher dose - Expect to initiate high-dose cohort in 2H 2020 NEW YORK and BASEL, Switzerland , June 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
Read More

PDF Version
Read More
Summary Toggle

05.28.2020

Summary Toggle Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference

Summary ToggleNEW YORK and BASEL, Switzerland , May 28, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that Parag Meswani , Pharm.D., SVP of Commercial Strategy and Operations, will
Read More

PDF Version
Read More
Summary Toggle

05.07.2020

Summary Toggle Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

Summary ToggleNEW YORK and BASEL, Switzerland , May 07, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced upcoming presentations regarding its investigational gene therapy programs,
Read More

PDF Version
Read More
Summary Toggle

04.24.2020

Summary Toggle Axovant Announces Full Prepayment of Outstanding Loan from Hercules Capital

Summary ToggleCompany’s balance sheet is now free of debt NEW YORK and BASEL, Switzerland , April 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had prepaid in full its $15.7 million
Read More

PDF Version
Read More
Summary Toggle

04.15.2020

Summary Toggle Axovant Announces Partnership with Invitae to Increase Access to Genetic Testing and Accelerate Diagnoses of GM1 and GM2 Gangliosidosis

Summary TogglePartnership to reduce barriers to genetic diagnosis through sponsored testing for lysosomal storage diseases Initiative supports identification of patients with GM1 and GM2 gangliosidosis who are currently misdiagnosed or undiagnosed NEW YORK and BASEL, Switzerland , April 15, 2020 (GLOBE NEWSWIRE)
Read More

PDF Version
Read More

Investors & Media Press Releases

Press Releases

Email Alerts

Print

Email

Search

Investors & Media Press Releases

Press Releases

Toolbar

Email Alerts

Print

Email

Search